Released Mar 11, 2016, before the open
10-K filed Mar 15, 2016, 75 days after period end · 0001493152-16-008049
Q4 2015 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$6.52M$6.52M derived−3.4% vs Q4 2014+7.3% vs Q3 2015
Net Income-$990.00K-$990.00K derivedN/M vs Q4 2014N/M vs Q3 2015
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$903,000N/M
Operating Cash Flowderived-$1,957,000N/M
Free Cash Flowderived-$2,167,000N/M
Margins · derived
Operating margin-13.8%+8.6 pt vs Q4 2014
Net margin-15.2%+10.3 pt vs Q4 2014
What the release said
The release
Same quarter
| Metric | Q4 2015dderived from reported figures | Q4 2014dderived from reported figures | Q4 2013dderived from reported figures | Q4 2012 |
|---|---|---|---|---|
| Revenue | $6.52M | $6.75M | $6.58M | $5.93M |
| Net Income | -$990.00K | -$1.72M | -$351.00K | $629.00K |
| EPS Diluted | — | — | — | $0.01 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ernexa Therapeutics Inc. · CIK 748592 · Engraved from SEC EDGAR